Fundamental innovation usually involves huge upfront costs, but the benefits are spread across various sectors of the economy. Given the large costs and limited appropriability of the benefits associated with fundamental innovations, individual firms underinvest in these innovations relative to...

We analyze the roles of entrepreneurs, venture capitalists (VC), and the government in financing fundamental innovations, defined as those with positive social value net of development costs, but negative net present values to innovating firms. We first analyze the case where the entrepreneur,...

In this paper, we review the theoretical and empirical literature on measuring the top management quality of firms, and its relation to various aspects of corporate financial policies and corporate innovation, and draw policy implications for enhancing corporate innovation. First, we discuss how...

We analyze, theoretically and empirically, how salience affects the market reaction to innovation announcements. Hypothesizing that equity market investors pay more attention to more salient announcements, we develop a dynamic model with limited investor attention of patent grant and FDA drug...

We analyze, theoretically and empirically, the implications of salience on innovation announcements in the biopharmaceutical industry. We hypothesize that equity market investors are more likely to pay attention to an innovation announcement that is more salient: thus, investors pay more...